$AXON Sio Gene Therapies Inc. Insider Trading
Get free email notifications about insider trading in Sio Gene Therapies Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Sio Gene Therapies Inc.. Insider overview, share value development, latest insider transactions and email notifications about new events in Sio Gene Therapies Inc. for free.
IRS Number: 853863315
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Trading Symbol: AXON
Company Address: 130 WEST 42ND STREET 26TH FLOOR NEW YORK 10036
Former name: Axovant Sciences, Inc., date of change: 2015-03-24
Former name: Roivant Neurosciences Ltd., date of change: 2015-03-09
Former name: Axovant Sciences Ltd., date of change: 2015-03-24
Former name: Axovant Gene Therapies Ltd., date of change: 2019-05-16
Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.
Market Capitalization: $1.28B
Prev close: $12.97
Average Daily Volume: 286,313
Days Low: $12.83
Year Low: $9.19
Year High: $17.66
Sio Gene Therapies Inc. Latest Insider Transactions
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Vuori Kristiina MD | Director | Option Exercise | A | 2.47 | 42,000 | 103,740 | 42,000 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Torti Frank | Director | Option Exercise | A | 2.47 | 42,000 | 103,740 | 42,000 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Sundaram Senthil Vel | Director | Option Exercise | A | 2.47 | 42,000 | 103,740 | 42,000 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Pande Atul | Director | Option Exercise | A | 2.47 | 42,000 | 103,740 | 42,000 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Modig Berndt | Director | Option Exercise | A | 2.47 | 42,000 | 103,740 | 42,000 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Nassif David W. | Chief Financial Off ... | Option Exercise | A | 2.47 | 239,000 | 590,330 | 239,000 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Nassif David W. | Chief Financial Off ... | Option Exercise | A | 2.47 | 239,000 | 590,330 | 239,000 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Corcoran Gavin | Chief R&D Officer | Option Exercise | A | 2.47 | 244,300 | 603,421 | 244,300 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Corcoran Gavin | Chief R&D Officer | Option Exercise | A | 2.47 | 244,300 | 603,421 | 244,300 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Cheruvu Pavan | Chief Executive Off ... | Option Exercise | A | 2.47 | 682,100 | 1,684,787 | 682,100 | |
| Apr 19 2021 | AXON | Sio Gene Therapies ... | Cheruvu Pavan | Chief Executive Off ... | Option Exercise | A | 2.47 | 682,100 | 1,684,787 | 682,100 | |
| Mar 24 2021 | AXON | Sio Gene Therapies ... | Cheruvu Pavan | Chief Executive Off ... | Buy | P | 2.48 | 100,000 | 248,180 | 180,426 | 80.4 K to 180.4 K (+124.34 %) |
| Mar 22 2021 | AXON | Sio Gene Therapies ... | Nassif David W. | Chief Financial Off ... | Option Exercise | D | 0.00 | 15,060 | 0 | 0 | |
| Mar 22 2021 | AXON | Sio Gene Therapies ... | Nassif David W. | Chief Financial Off ... | Grant | A | 0.00 | 15,060 | 0 | 34,004 | 18.9 K to 34 K (+79.50 %) |
| Mar 19 2021 | AXON | Sio Gene Therapies ... | Corcoran Gavin | Chief R&D Officer | Option Exercise | D | 0.00 | 16,001 | 0 | 0 |